RxDoctor Payments Data

Nolan Kleinjan, MD

Internal Medicine · la Crosse, WINPI 1386131100

Payments from drug & device makers

$352in general payments, 2019–2025

Across 21 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$126
  • Lundbeck LLC$59
  • E.r. Squibb & Sons, L.L.C.$53
  • Lilly USA, LLC$46
  • Amgen$21
  • Pfizer$16
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$352100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$352 in reported general payments places this provider in the 80th percentile of 1,411 internal medicine providers in Wisconsin.

See all internal medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$26,403
Medicare patients
92
Services billed
272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide136$134,825
JardianceEmpagliflozin138$129,038
EliquisApixaban240$129,035
OzempicSemaglutide48$53,033
BiktarvyBictegrav/Emtricit/Tenofov Ala12$46,819
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$33,763
MounjaroTirzepatide27$31,175
EntrestoSacubitril/Valsartan37$24,827
Breo ElliptaFluticasone/Vilanterol48$19,134
XareltoRivaroxaban30$18,386
Tresiba Flextouch U-200Insulin Degludec26$15,097
MyrbetriqMirabegron25$10,632
Fentanyl84$9,556
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$9,252
Praluent PenAlirocumab16$7,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$46$166,000163 claims
PfizerEliquis$16$129,035240 claims
Novo NordiskOzempic$126$53,03348 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,411 internal medicine providers in Wisconsin.

Other internal medicine in la Crosse

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →